Sugi Predict

Sugi Predict / Compounds / SCHEMBL1031941

SCHEMBL1031941

SCHEMBL1031941

OCCNCc1cc[c]cc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PDCD1 Q15116 4/20 0.47
▸ CD274 Q9NZQ7 4/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ GSR P00390 2/20 0.42
▸ MAOA P21397 1/20 0.39
▸ MCHR1 Q99705 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1625535 0.84 SMN1; SMN2 (0.64) SMN1; SMN2PDCD1CD274ALDH1A1TSHR
SCHEMBL5132875 0.81 SIGMAR1 (0.41) SMN1; SMN2GAAMAPT
SCHEMBL9654444 0.78 MC4R (0.47) SMN1; SMN2ALDH1A1MEN1KMT2ATDP1
SCHEMBL10657165 0.78 TDP1 (0.43) SMN1; SMN2MEN1KMT2ATDP1MAOA
SCHEMBL7427957 0.78 HRH4 (0.47) SMN1; SMN2MEN1KMT2ATDP1MAOA
SCHEMBL19401259 0.77 MEN1 (0.73) SMN1; SMN2PDCD1CD274MEN1KMT2A
SCHEMBL177039 0.77 MEN1 (0.73) SMN1; SMN2PDCD1CD274MEN1KMT2A
SCHEMBL27663515 0.76 SMN1; SMN2 (0.45) SMN1; SMN2PDCD1CD274ALDH1A1TSHR
Hydrochloric Acid SCHEMBL6897315 0.76 SMN1; SMN2 (0.72) SMN1; SMN2PDCD1CD274MEN1KMT2A
SCHEMBL1822940 0.76 SMN1; SMN2 (0.56) SMN1; SMN2PDCD1CD274ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 — — EP claimed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 — — US claimed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 — — US claimed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 — — EP claimed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 — — WO claimed
US-6353017-B1 INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS NOVARTIS AG (CH) 2002-03-05 — — US claimed
US-20240238427-A1 METHODS OF TREATING AN EYE DISORDER KODIAK SCIENCES INC. 2024-07-18 — — US disclosed
CN-118284413-A Composition for localized bone formation 奥斯菲治疗有限公司 2024-07-02 — — CN disclosed
US-20240209076-A1 USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF KODIAK SCIENCES INC. 2024-06-27 — — US disclosed
US-20240197810-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC. 2024-06-20 — — US disclosed
US-20240084043-A1 METHODS OF TREATING AN EYE DISORDER KODIAK SCIENCES INC. 2024-03-14 — — US disclosed
US-11912784-B2 Methods of treating an eye disorder KODIAK SCIENCES INC. (US) 2024-02-27 — — US disclosed
EP-4323399-A1 METHODS OF TREATING AN EYE DISORDER Kodiak Sciences Inc. (US) 2024-02-21 — — EP disclosed
US-20040029814-A1 Dipeptide nitriles ALTMANN EVA (CH) 2004-02-12 — — US disclosed
WO-2003106615-A2 POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION GENEPROT, INC. (CH) 2003-12-24 — — WO disclosed
US-6353017-B1 INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS NOVARTIS AG (CH) 2002-03-05 — — US disclosed
WO-2000048993-A1 ARYLAMINOALKYLAMIDES NOVARTIS AG (CH) 2000-08-24 — — WO disclosed
EP-1028942-A2 DIPEPTIDE NITRILES Novartis AG (CH) 2000-08-23 — — EP disclosed
WO-1999024460-A2 DIPEPTIDE NITRILES NOVARTIS AG (CH) 1999-05-20 — — WO disclosed
US-4762845-A BACTERICIDES ABBOTT LABORATORIES (US) 1988-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912784-B2 Methods of treating an eye disorder VEGFA, FLT4, FLT1 SMN1; SMN2 1353/4885PDCD1 2421/4885CD274 2428/4885
US-20240084043-A1 METHODS OF TREATING AN EYE DISORDER VEGFA, FLT4, FLT1 SMN1; SMN2 1353/4885PDCD1 2421/4885CD274 2428/4885
US-20240238427-A1 METHODS OF TREATING AN EYE DISORDER ALDH1A2, PDE6D, CRYAB SMN1; SMN2 1945/4885PDCD1 4815/4885CD274 4870/4885
US-20240209076-A1 USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF IL6, FLT4, TEK SMN1; SMN2 3739/4885PDCD1 609/4885CD274 260/4885
US-20040029814-A1 Dipeptide nitriles NOS1, CTSL, CTSS SMN1; SMN2 4277/4885PDCD1 4499/4885CD274 4459/4885
US-20240197810-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES PHOSPHO1, MSN, ZW10 SMN1; SMN2 1821/4885PDCD1 4544/4885CD274 3865/4885
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SMN1; SMN2 1421/4885PDCD1 890/4885CD274 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.